Last updated: February 24, 2026
What Is the Drug Under NDC 70000-0425?
NDC 70000-0425 refers to a specific pharmaceutical product. Based on available databases, this NDC corresponds to Tocilizumab (brand name: Actemra), a monoclonal antibody used to treat rheumatoid arthritis, cytokine release syndrome, and other immune-mediated conditions.
Market Size and Key Drivers
Therapeutic Area Overview
Tocilizumab operates primarily within the immunology and rheumatology markets. Its indications include:
- Rheumatoid arthritis (RA)
- Juvenile idiopathic arthritis (JIA)
- Cytokine release syndrome (CRS)
- Giant cell arteritis (GCA)
Estimated Market Volume
Global demand for Tocilizumab has grown due to expanding indications and off-label uses. In 2022, the global market generated approximately $4.2 billion, with a compound annual growth rate (CAGR) of 8.5% from 2018 to 2022 [1].
Key Regional Markets
| Region |
2022 Sales (USD billion) |
CAGR (2018-2022) |
Key Factors |
| United States |
$2.2 |
7.0% |
High prevalence of RA, strong reimbursement coverage |
| Europe |
$1.1 |
8.5% |
Expanding approval for GCA and JIA |
| Asia-Pacific |
$0.55 |
10% |
Growing access, increasing diagnosis rates |
| Rest of World |
$0.35 |
9% |
Limited but growing market presence |
Competitive Landscape
Major players include:
- Roche (manufactures Actemra)
- Novartis (offering alternative IL-6 inhibitors)
- Pfizer, Johnson & Johnson (developing biosimilars)
Patent expiration of key formulations is expected around 2024-2026, which will influence generic and biosimilar market entry.
Price Analysis and Projection
Current Pricing
Wholesale acquisition cost (WAC) for a 80 mg dose in the U.S. averages approximately $800 per vial. Monthly treatment regimens typically require 4-8 vials, depending on patient weight and indication, leading to approximate monthly treatment costs ranging from $3,200 to $6,400 [2].
Pricing Trends
- Pre-Patent Expiry: Prices remained stable, with minimal discounts.
- Post-Patent Expiry: Introduction of biosimilars in Europe began in 2021. U.S. biosilimar entries are expected post-2024, which could reduce prices by 15-30% initially, with further reductions over time.
Forecasted Price Trends (Next 5 Years)
| Year |
Estimated Price per Vial (USD) |
Key Assumptions |
| 2023 |
$800 |
No biosimilar competition, stable pricing |
| 2024 |
$750 |
Biosimilar launches in Europe; U.S. approval pending |
| 2025 |
$700 |
Biosimilars gain market share; price discounts increase |
| 2026 |
$650 |
Increased biosimilar penetration, potential price wars |
| 2027 |
$600 |
Continued competition, reduced manufacturing costs |
Price Drivers
- Biosimilar market penetration
- Payer negotiation leverage
- Manufacturing efficiencies
- Regulatory policies regarding biosimilar substitution
Regulatory and Policy Impact
U.S. FDA approval for biosimilars is anticipated for several candidates around 2024-2025. European Medicines Agency (EMA) approved biosimilars like FleximiR in 2021, contributing to market competition.
Switching policies and reimbursement frameworks influence pricing strategies. Favorable policies for biosimilars can accelerate price reduction.
Revenue and Market Share Projections
| Year |
Global Revenue (USD billion) |
Market Share of Biosimilars |
Key Factors |
| 2023 |
$4.2 |
0% |
Patent protected, no biosimilar competition |
| 2024 |
$4.2 |
5% |
Biosimilar approval in Europe, U.S. pending |
| 2025 |
$4.5 |
15% |
Biosimilars entering U.S. market |
| 2026 |
$4.8 |
25% |
Increased biosimilar adoption, price competition |
| 2027 |
$5.0 |
35% |
Biosimilar market stabilization, patent cliffs fully realized |
Summary
- The drug corresponding to NDC 70000-0425 (Tocilizumab) holds a significant position within immunology, with revenues approximating $4.2 billion in 2022.
- Market growth will continue driven by expanding indications and off-label use.
- Biosimilar entry beginning around 2024 will likely reduce prices by 15-30%, with further declines over subsequent years.
- Pricing remains sensitive to regulatory changes, market penetration rates, and reimbursement policies.
Key Takeaways
- The global market for Tocilizumab is expected to grow at approximately 8% CAGR until 2027.
- Entry of biosimilars in the U.S. in 2024-2025 will be a catalyst for price reductions.
- Existing patent protections limit generic competition until the mid-2020s.
- Price per vial is projected to decrease from about $800 in 2023 to around $600 by 2027.
- Market share of biosimilars is expected to comprise over 35% of total sales by 2027.
FAQs
1. What is the patent expiry date for the original Tocilizumab formulations?
Patent protections are expected to expire around 2024-2026, depending on the specific formulation and jurisdiction.
2. How will biosimilar entry impact pricing?
Biosimilar entry can decrease prices by 15-30% initially in Europe and potentially more gradually in the U.S., affecting both wholesale and patient access costs.
3. Are there any regulatory hurdles for biosimilar approval in the U.S.?
The FDA has a pathway for biosimilar approval, but gaining interchangeability status remains a challenge and varies by product.
4. Which regions have the highest growth potential for this drug?
Asia-Pacific and emerging markets show the highest growth potential due to increasing healthcare access and prevalence of target diseases.
5. What factors could disrupt these price projections?
Regulatory changes, patent litigation, market saturation, and unexpected safety concerns could alter the trajectory.
References
[1] MarketWatch. (2023). Global immunology drugs market size & growth outlook. Retrieved from https://www.marketwatch.com
[2] IQVIA. (2022). National prescription data and drug pricing analysis.
